Pages that link to "Q46229463"
The following pages link to PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. (Q46229463):
Displaying 50 items.
- Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal (Q26744536) (← links)
- Cancer stem cells (CSCs), cervical CSCs and targeted therapies (Q26747144) (← links)
- The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials (Q26751155) (← links)
- Multiple myeloma cancer stem cells (Q26752365) (← links)
- Cancer stem cells in small cell lung cancer (Q26767026) (← links)
- Cancer Stem Cell Plasticity Drives Therapeutic Resistance (Q26770274) (← links)
- Cancer stem cell targeted therapy: progress amid controversies. (Q26779931) (← links)
- Stem cell guidance through the mechanistic target of rapamycin (Q26795544) (← links)
- Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives (Q28071388) (← links)
- Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells (Q28078154) (← links)
- EMT, CTCs and CSCs in tumor relapse and drug-resistance (Q28082935) (← links)
- VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo (Q35708311) (← links)
- PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma (Q35944343) (← links)
- Regeneration in the nervous system with erythropoietin (Q36247651) (← links)
- High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant (Q36544355) (← links)
- Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin (Q37337887) (← links)
- HPV16 E6-E7 induces cancer stem-like cells phenotypes in esophageal squamous cell carcinoma through the activation of PI3K/Akt signaling pathway in vitro and in vivo (Q37636751) (← links)
- STROBE-compliant integrin through focal adhesion involve in cancer stem cell and multidrug resistance of ovarian cancer (Q37727225) (← links)
- Targeting the Mammalian Target of Rapamycin in Lung Cancer. (Q37741531) (← links)
- Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer (Q38514906) (← links)
- Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders (Q38607849) (← links)
- Therapeutic potential of mTOR inhibitors for targeting cancer stem cells (Q38648562) (← links)
- Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer (Q38655453) (← links)
- Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer (Q38748709) (← links)
- JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers (Q38753975) (← links)
- Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature. (Q38813996) (← links)
- Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma (Q38850277) (← links)
- Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance (Q38950219) (← links)
- Pharmacological and immunological targeting of tumor mesenchymalization (Q39029043) (← links)
- Inhibition of FAK kinase activity preferentially targets cancer stem cells (Q41612992) (← links)
- MicroRNAs and SIRT1: A Strategy for Stem Cell Renewal and Clinical Development? (Q41902364) (← links)
- Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer (Q42317503) (← links)
- Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. (Q42505998) (← links)
- Inhibition of PI3K Signalling Selectively Affects Medulloblastoma Cancer Stem Cells (Q43193981) (← links)
- VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim. (Q47107700) (← links)
- Reprogramming Factors Remodel Melanoma Cell Phenotype by Changing Stat3 Expression (Q47118268) (← links)
- Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop. (Q47137624) (← links)
- Iron depletion is a novel therapeutic strategy to target cancer stem cells (Q47152171) (← links)
- New Advances and Challenges of Targeting Cancer Stem Cells. (Q48588244) (← links)
- Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics (Q49167162) (← links)
- Cancer stem cells and evolving novel therapies: a paradigm shift (Q50072739) (← links)
- Dual inhibition of PI3K and mTOR by VS-5584 suppresses thrombus formation (Q50647961) (← links)
- Targeting SRC Coactivators Blocks the Tumor-Initiating Capacity of Cancer Stem-like Cells (Q50946441) (← links)
- A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase. (Q52668830) (← links)
- Novel molecular insights and new therapeutic strategies in osteosarcoma (Q57814118) (← links)
- Epithelial-mesenchymal transition: a new target in anticancer drug discovery (Q87179773) (← links)
- Targeting mTOR for cancer therapy (Q91660586) (← links)
- Cancer stem cells-driven tumor growth and immune escape: the Janus face of neurotrophins (Q91777772) (← links)
- Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy (Q92344290) (← links)
- Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma (Q93376636) (← links)